CN107893115B - Alkbh1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途 - Google Patents
Alkbh1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途 Download PDFInfo
- Publication number
- CN107893115B CN107893115B CN201710964814.0A CN201710964814A CN107893115B CN 107893115 B CN107893115 B CN 107893115B CN 201710964814 A CN201710964814 A CN 201710964814A CN 107893115 B CN107893115 B CN 107893115B
- Authority
- CN
- China
- Prior art keywords
- alkbh1
- gene
- expression
- tumors
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 45
- 230000014509 gene expression Effects 0.000 title claims abstract description 42
- 101100269633 Homo sapiens ALKBH1 gene Proteins 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title description 7
- 101000836620 Homo sapiens Nucleic acid dioxygenase ALKBH1 Proteins 0.000 claims abstract description 43
- 201000007270 liver cancer Diseases 0.000 claims abstract description 22
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 22
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 18
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 18
- 102100027051 Nucleic acid dioxygenase ALKBH1 Human genes 0.000 claims description 42
- 108020004459 Small interfering RNA Proteins 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 7
- 230000004709 cell invasion Effects 0.000 abstract description 7
- 206010017758 gastric cancer Diseases 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 7
- 238000012986 modification Methods 0.000 abstract description 7
- 201000011549 stomach cancer Diseases 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000007067 DNA methylation Effects 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000018732 detection of tumor cell Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000195585 Chlamydomonas Species 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010005336 Histone H2a Dioxygenase AlkB Homolog 1 Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000959161 Mus musculus Nucleic acid dioxygenase ALKBH1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000044380 human ALKBH1 Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了人ALKBH1基因在制备诊断和/或治疗肿瘤产品中的应用。本发明通过检测胃癌、肝癌病人肿瘤组织中ALKBH1基因表达情况,发现其表达水平明显升高。通过构建ALKBH1基因过表达/沉默的肝癌和卵巢癌细胞株分别与对照组相比,其DNA6mA修饰水平、增殖能力、细胞迁移率及细胞侵袭能力等均产生显著变化。ALKBH1基因及其表达产物作为诊断肿瘤的标志物,使肿瘤诊断更加准确、快速,作为制备治疗肿瘤药物的靶基因,为治疗肿瘤提供了新的治疗靶点和治疗途径。
Description
技术领域
本发明属于生物技术和医学领域,具体涉及ALKBH1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的应用。
背景技术
肿瘤是威胁人类健康的主要疾病,其发生发展是一个多步骤的过程。虽然临床治疗方案已在不断改进,但患者的五年生存率仍很低,早诊断、早治疗是提高肿瘤患者生存率的关键。肿瘤的发生发展涉及到癌基因的活化和抑癌基因的失活,通过检测发生改变的癌基因和抑癌基因,可以在分子水平上早期检测到肿瘤的发生,从而为及时的诊断治疗创造机会。
随着对肿瘤研究的深入,人们发现表观遗传修饰尤其是DNA甲基化在肿瘤发生发展中扮演着一个重要的角色。DNA甲基化是指生物体在DNA甲基转移酶的催化下,将甲基转移到特定的碱基上的过程。DNA甲基化可以发生在腺嘌呤的N-6位、胞嘧啶的N-4位、鸟嘌呤的N-7位或胞嘧啶的C-5位等。一般认为真核生物中最主要的甲基化修饰是生成5-甲基胞嘧啶(5mC),而N6-甲基腺嘌呤(6mA)是原核生物中最普遍的DNA修饰。
随着深度测序的发展,6mA陆续被发现存在于少数的真核生物中,包括衣藻、线虫、黑腹果蝇、真菌、小鼠、斑马鱼及猪。而由于丰度低或检测技术有限的原因,DNA 6mA修饰此前被认为不存在于人类基因组中。但发明者证明,6mA广泛分布于人类基因组DNA中。在外显子区域中,6mA密度显著增加,与基因转录激活相关。GO分析表明,6mA可能在G蛋白偶联受体的调控中发挥重要作用,而G蛋白偶联受体与包括癌症等多种疾病有关,因此6mA可能参与调控癌症等疾病。
已有报道称ALKBH1是小鼠的DNA 6mA脱甲基酶,而且人源ALKBH1与鼠源ALKBH1具有高度同源性。氨基酸序列Oncomine数据库中ALKBH1的mRNA在肺癌、前列腺癌、睾丸癌、肾细胞癌等癌症中高表达。发明者通过体外甲基化实验证明ALKBH1可抑制DNA 6mA修饰水平,在人肿瘤中可作为DNA 6mA的脱甲基酶。但ALKBH1在肿瘤的生物学功能和可能的作用机制尚无文献报道。
发明内容
本发明的目的在于,提供了一种用于诊断肿瘤的试剂盒,一种用于治疗肿瘤的药物组合物,以及ALKBH1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途。
为实现上述目的,所采取的技术方案:一种用于诊断肿瘤的试剂盒,所述试剂盒包括检测ALKBH1基因表达水平的试剂。
优选地,所述试剂包括用于扩增ALKBH1基因的引物。
优选地,所述引物包括序列如SEQ ID NO:1所示的上游引物和序列如SEQ ID NO:2所示的下游引物。
本发明提供了ALKBH1基因及其表达产物在制备用于诊断肿瘤的试剂盒中的用途。
本发明提供了检测ALKBH1基因表达水平的试剂在制备用于诊断肿瘤的试剂盒中的用途。
本发明提供了一种用于治疗肿瘤的药物组合物,所述药物组合物包括降低ALKBH1基因表达的试剂、ALKBH1蛋白中和剂中的至少一种。
优选地,所述降低ALKBH1基因表达的试剂包括沉默ALKBH1基因表达的siRNA,所述siRNA包括由SEQ IN NO:5和SEQ IN NO:6组成的siRNA、由SEQ IN NO:7和SEQ IN NO:8组成的siRNA中的至少一种。
本发明提供了ALKBH1基因及其表达产物在制备或筛选用于治疗肿瘤的药物中的用途。
本发明提供了降低ALKBH1基因表达的试剂、ALKBH1蛋白中和剂中的至少一种在制备用于治疗肿瘤的药物中的用途。
优选地,所述肿瘤包括胃癌、肝癌或卵巢癌。
本发明的有益效果是:
1)本发明通过设计ALKBH1引物进行RT-PCR证实胃癌、肝癌病人肿瘤组织中ALKBH1基因表达情况,发现其表达水平明显升高,因此,ALKBH1可作为多种肿瘤的诊断标志。
2)本发明对ALKBH1基因进行了体外细胞功能学的研究。通过构建ALKBH1基因过表达的肝癌和卵巢癌细胞株分别与其对照组相比,其DNA 6mA修饰水平显著下调,其增殖能力、细胞迁移率及细胞侵袭能力等均显著提高。通过将ALKBH1基因表达下调的肝癌和卵巢癌细胞株与对照组相比,其DNA 6mA修饰水平显著上升,其增殖能力、细胞迁移率及细胞侵袭能力等均显著减弱。ALKBH1基因及其表达产物可以应用在制备治疗多种肿瘤的药物中。
ALKBH1基因及其表达产物作为诊断肿瘤的标志物,使肿瘤诊断更加准确、快速,作为制备治疗肿瘤药物的靶基因为治疗肿瘤提供了新的治疗靶点和治疗途径。
附图说明
图1为本发明实施例1中RT-PCR检测胃癌及肝癌组织中ALKBH1表达结果对比图;
图2为本发明实施例2中过表达ALKBH1的肝癌细胞株MHCC-LM3、SK-hep1及卵巢癌细胞株OVCAR-3表达ALKBH1的结果对比图。
图3为本发明实施例3中过表达ALKBH1的肝癌细胞株MHCC-LM3、SK-hep1及卵巢癌细胞株OVCAR-3的DNA 6mA水平下降。
图4为本发明实施例4中过表达ALKBH1的肝癌细胞株MHCC-LM3、SK-hep1及卵巢癌细胞株OVCAR-3生长速度上升。
图5为本发明实施例5、6中过表达ALKBH1的肝癌细胞株MHCC-LM3、SK-hep1及卵巢癌细胞株OVCAR-3迁移、侵袭率上升。在肝癌和卵巢癌细胞中上调ALKBH1基因后的细胞迁移、侵袭实验结果示意图。
图6为本发明实施例2中沉默ALKBH1的肝癌细胞株BEL-7402、SMMC-7721及卵巢癌细胞株OVCAR-3表达ALKBH1的结果对比图。
图7为本发明实施例3中沉默ALKBH1的肝癌细胞株BEL-7402、SMMC-7721及卵巢癌细胞株OVCAR-3的DNA 6mA水平上升。
图8为本发明实施例4中沉默ALKBH1的肝癌细胞株BEL-7402、SMMC-7721及卵巢癌细胞株OVCAR-3生长速度下降。
图9为本发明实施例5、6中沉默ALKBH1的肝癌细胞株BEL-7402、SMMC-7721及卵巢癌细胞株OVCAR-3迁移、侵袭率下降。在肝癌和卵巢癌细胞中下调ALKBH1基因后的细胞迁移、侵袭实验结果示意图。
具体实施方式
为更好的说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。
本发明首先通过RT-PCR检测人胃癌及肝癌组织中ALKBH1表达情况。结果表明,在人胃癌及肝癌组织中ALKBH1表达明显上调。结果如图1所示。
进一步,我们对ALKBH1进行了体外细胞功能学的研究,通过将ALKBH1基因序列在肝癌和卵巢癌细胞株过表达/沉默,以建立该基因表达上调/下调的细胞株。结果表明,过表达ALKBH1基因的肝癌和卵巢癌细胞株分别与对照组相比,其DNA 6mA水平显著下降,增殖能力、细胞迁移率及细胞侵袭能力等均显著升高。沉默ALKBH1基因的肝癌和卵巢癌细胞株分别与对照组相比,其DNA 6mA水平显著升高,增殖能力、细胞迁移率及细胞侵袭能力等均显著下降。因此,ALKBH1基因及其表达产物可以应用在制备治疗肿瘤的药物中。结果如图2~9所示。
本发明所涉及的技术均为分子克隆常规技术手段,其中涉及的酶、引物、试剂以及反应条件在未作说明的情况下均可根据本领域技术人员的经验进行合理选择,其中涉及试剂耗材属于市售的普通产品,其中涉及的检测手段以及仪器也均为本领域技术人员所熟知并熟练掌握。
下面通过实施例和试验例对本发明的技术方案做进一步的说明,但不应理解为对本发明的限制。
实施例1:RT-PCR反应检测ALKBH1基因在胃癌及肝癌组织中的表达。
具体实验方案如下:
1.RNA提取
1)组织处理:取10mg左右组织加入1mlTrizol,用匀浆机匀浆;离心15分钟,12000g,取上清。
2)向上清中加入200ul氯仿,上下用力颠倒混匀半分钟,静置3分钟。
3)4℃,12000g离心15分钟,此时可见裂解液分三层:上层为水相的RNA;中层为DNA,脂类等;下层为细胞残渣,蛋白,多糖等。
4)取上清到新的EP管内;加入等体积的异丙醇,混匀,静置10分钟后,4℃,12000g离心10分钟。
5)小心去掉上清,注意不要丢失RNA沉淀,加入1ml75%乙醇,上下颠倒,使沉淀块重悬起。
6)4℃,12000g离心10分钟,小心去掉上清,尽量吸干管壁的液体,注意不要丢失RNA沉淀,若沉淀松动可再次离心。晾干约15分钟,至管壁无液体。
7)加入适量体积(20-30ul)的DEPC水溶解RNA,58℃水浴10分钟。
8)取出2ul定量,测量buffer:10mMTrisCl(pH7.8),根据定量结果进行逆转录。(1A260=40μg/ml,A260/A280=1.8~2.1)。
2.cDNA逆转录
实验体系
M-MLV Reverse Transcriptase:
3.引物:使用的引物如下所列:
4.PCR:以GAPDH作为内参。PCR的反应体系:每个反应管中分别加入2μl 10×Buffer,分别加入2μl dNTP,1μl正向引物,1μl反向引物,1μl cDNA模板,0.2μl Taq酶,加水至20μl。PCR反应条件如下:94℃,5分钟预变性;94℃,30秒变性;55℃,30秒退火72℃,30秒延伸;35个循环,琼脂糖凝胶电泳检测PCR扩增产物,结果见图1。
实施例2:构建ALKBH1过表达/沉默细胞
(1)将细胞消化成单细胞悬液,计数,以5×105个/孔的浓度接种至6孔板中,37℃、5%CO2培养箱中培养过夜。
(2)取2μg过表达ALKBH1质粒溶于250μl opti-MEM中;用RNase-free的去离子水溶解siALKBH1至终浓度为20μM,取20μl溶于250μl opti-MEM中,混匀、静置。
其中,相关构建过表达ALKBH1质粒的引物序列如下:
Sense:5'-CGGGGTACCGCGAGATGGGGAAGATGGCAGC-3'(SEQ ID NO:1)
Anti-sense:5'-CGGAATTCTTACTTGTCATCGTCGTCCTTGTAGTCGCTGTCAGGGTTTATCCTGGC-3'(SEQ ID NO:2)。
其中,相关siRNA序列如下:
siALKBH1#1-sense:5'-GCAAGCCUAUGGACUCAAATT-3'(SEQ ID NO:5)
siALKBH1#1-anti-sense:5'-UUUGAGUCCAUAGGCUUGCTT-3'(SEQ ID NO:6);
siALKBH1#2-sense:5'-GGAAUCCACGUAGACAGAUTT-3'(SEQ ID NO:7),
siALKBH1#2anti-sense:5'-AUCUGUCUACGUGGAUUCCTT-3'(SEQ ID NO:8);
negative control siRNA-sense:5'-GCACAAGCUGGAGUACAACUACATT-3'(SEQ IDNO:9),
negative control siRNA-anti-sense:5
'-UGUAGUUGUACUCCAGCUUGUGCTT-3'(SEQ ID NO:10)。
(3)将5μl LipofectamineTM 2000溶于250μl opti-MEM中,轻轻混匀,室温静置5min。
(4)将2跟3的两管混匀,室温静置20min,滴加至6孔板孔中,混匀,37℃、5%CO2培养箱中培养。
(5)4小时后,吸去转染培养基,加入2ml完全培养基,继续培养。
(6)48小时后,提取细胞RNA,并逆转录成cDNA,采用RT-PCR检测ALKBH1的表达情况。
结果见图2、6,转染使细胞过表达/沉默ALKBH1有效。
实施例3:验证ALKBH1与细胞DNA 6mA水平相关
(1)提取过表达/沉默ALKBH1基因的肿瘤细胞的DNA,并在95℃变性10min,冰上冷却5min。
(2)把DNA滴在硝酸纤维膜上室温干燥5min。
(3)将膜置于80℃烘干2h,再用封闭液室温封闭1.5h。
(4)将膜与特异性6ma抗体4℃孵育过夜。
(5)将膜与HRP-conjugated二抗室温孵育1.5h后于暗室曝光。
结果见图3、7,ALKBH1表达上调的肿瘤细胞株的DNA 6mA水平下降,ALKBH1表达下调的肿瘤细胞株DNA6mA水平上升。这些结果表明ALKBH1可以调控肿瘤细胞的DNA 6mA水平。
实施例4:过表达/沉默ALKBH1基因的肿瘤细胞增殖能力测定
(1)将过表达/沉默ALKBH1的细胞株及对照细胞消化成单细胞悬液,计数,调整细胞浓度为1×105个/ml,分到12孔板,每孔2ml。
(2)37℃、5%CO2培养箱中培养,每天镜下观察集落形成情况并拍照。
结果见图4、8,ALKBH1表达上调的肿瘤细胞株集落形成能力上升,ALKBH1表达下调的肿瘤细胞株集落形成能力下降。集落形成能力代表细胞的增殖能力。这些结果表明ALKBH1可以调控肿瘤细胞的增殖能力。
实施例5:过表达/沉默ALKBH1基因的肿瘤细胞迁移能力检测
(1)胰酶消化成单细胞悬液,计数,用无血清培养基调整细胞浓度至1×106/ml。
(2)加入100μl细胞悬液至小室上室,在下室中加入600μl含不同浓度胎牛血清的完全培养基。37℃、5%CO2培养箱中孵育24h。
(3)取出小室,用棉签擦去上室的细胞,4%多聚甲醛固定10min,PBS洗涤一次,结晶紫染色10min,PBS洗涤一次,显微镜观测并拍照。
结果见图5、9,ALKBH1表达上调的肿瘤细胞株迁移率增加,ALKBH1表达下调的肿瘤细胞株迁移率减少。这些结果表明ALKBH1调控肿瘤细胞的迁移能力。
实施例6:过表达/沉默ALKBH1基因的肿瘤细胞侵袭能力检测
(1)将Matrigel置于4℃中过夜溶解,用预冷的基础培养基按Matrigel:培养基=1:3的比例稀释,取40μl加入预冷的Transwell小室中,动作要慢,避免产生气泡。
(2)37℃孵育2小时使Matrigel凝固。
(3)分别在上下室加入100μl和600μl基础培养基,37℃水合过夜。次日吸去培养基。
(4)实验细胞胰酶消化后,取适量细胞悬液,800rpm离心5分钟。
(5)吸去上清,用基础培养基重悬细胞后,细胞计数并用基础培养基调整细胞浓度至1×106/ml,取100μl加入至Transwell小室上室,在下室加入600μl完全培养基。
(6)放入培养箱中培养24小时后,取出小室,用棉签擦去上室的细胞,4%多聚甲醛固定15分钟,PBS洗涤一次,1%结晶紫染色10分钟,PBS洗涤一次,显微镜下观察细胞是否穿过小孔。如有穿过,终止其他实验组,拍照并统计穿过的细胞数。
结果见图5、9,ALKBH1表达上调的肿瘤细胞株侵袭能力上升,ALKBH1表达下调的肿瘤细胞株侵袭能力下降。这些结果表明ALKBH1调控肿瘤细胞的侵袭能力。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
序列表
<110> 广州医科大学附属第三医院、中山大学中山眼科中心、广州库基生物科技有限公司
<120> ALKBH1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途
<160> 10
<170> PatentIn version 3.5
<210> 1
<211> 31
<212> DNA
<213> 人工序列
<400> 1
cggggtaccg cgagatgggg aagatggcag c 31
<210> 2
<211> 56
<212> DNA
<213> 人工序列
<400> 2
cggaattctt acttgtcatc gtcgtccttg tagtcgctgt cagggtttat cctggc 56
<210> 3
<211> 20
<212> DNA
<213> 人工序列
<400> 3
cgaccacttt gtcaagctca 20
<210> 4
<211> 20
<212> DNA
<213> 人工序列
<400> 4
aggggtctac atccgaactg 20
<210> 5
<211> 21
<212> DNA
<213> 人工序列
<400> 5
gcaagccuau ggacucaaat t 21
<210> 6
<211> 21
<212> DNA
<213> 人工序列
<400> 6
uuugagucca uaggcuugct t 21
<210> 7
<211> 21
<212> DNA
<213> 人工序列
<400> 7
ggaauccacg uagacagaut t 21
<210> 8
<211> 21
<212> DNA
<213> 人工序列
<400> 8
aucugucuac guggauucct t 21
<210> 9
<211> 25
<212> DNA
<213> 人工序列
<400> 9
gcacaagcug gaguacaacu acatt 25
<210> 10
<211> 25
<212> DNA
<213> 人工序列
<400> 10
uguaguugua cuccagcuug ugctt 25
Claims (2)
1.降低ALKBH1基因表达的试剂、ALKBH1蛋白中和剂中的至少一种在制备用于治疗肿瘤的药物中的用途,其特征在于,所述肿瘤为肝癌或卵巢癌。
2.根据权利要求1所述的用途,其特征在于,所述降低ALKBH1基因表达的试剂包括沉默ALKBH1基因表达的siRNA,所述siRNA包括由SEQ ID NO:5和SEQ ID NO:6组成的siRNA、由SEQ ID NO:7和SEQ ID NO:8组成的siRNA中的至少一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710964814.0A CN107893115B (zh) | 2017-10-17 | 2017-10-17 | Alkbh1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710964814.0A CN107893115B (zh) | 2017-10-17 | 2017-10-17 | Alkbh1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107893115A CN107893115A (zh) | 2018-04-10 |
CN107893115B true CN107893115B (zh) | 2021-06-04 |
Family
ID=61802745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710964814.0A Active CN107893115B (zh) | 2017-10-17 | 2017-10-17 | Alkbh1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107893115B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109239349B (zh) * | 2018-07-25 | 2021-08-03 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | 人附睾蛋白4作为类风湿关节炎诊断标志物的应用 |
CN112881693B (zh) * | 2021-01-26 | 2024-01-30 | 河南省人民医院 | 一组肿瘤相关抗原在制备肝癌早期筛查试剂盒中的应用 |
CN116445516B (zh) * | 2023-05-30 | 2024-07-12 | 杭州师范大学 | Alkbh1作为脂肪细胞衰老标志物的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017161138A1 (en) * | 2016-03-16 | 2017-09-21 | Yale University | Compositions and methods for detecting n6-methyladenine in the mammalian genome |
-
2017
- 2017-10-17 CN CN201710964814.0A patent/CN107893115B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017161138A1 (en) * | 2016-03-16 | 2017-09-21 | Yale University | Compositions and methods for detecting n6-methyladenine in the mammalian genome |
Non-Patent Citations (3)
Title |
---|
Chuan-Le Xiao, et al..N6-Methyladenine DNA Modification in Human Genome.《bioRxiv》.2017,第12页第2段、第13页第2段第5-8行,第18页第1段,第37页图6. * |
DNA N6-methyladenine demethylase ALKBH1 enhances osteogenic differentiation of human MSCs;Chenchen Zhou, et al.;《Bone Research》;20161011;第2页右栏第3段、表1 * |
N6-Methyladenine DNA Modification in Human Genome;Chuan-Le Xiao, et al.;《bioRxiv》;20170816;第12页第2段、第13页第2段第5-8行,第18页第1段,第37页图6 * |
Also Published As
Publication number | Publication date |
---|---|
CN107893115A (zh) | 2018-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017200853B2 (en) | MiRNA and its diagnostic therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway | |
CN107760784B (zh) | 环状RNA circ-FOXP1的用途 | |
CN107828888B (zh) | 环状RNA circ-PTPRA的用途 | |
WO2018024034A1 (zh) | 环状RNA circ-NFATC3及其用途 | |
CN107893115B (zh) | Alkbh1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途 | |
US9421218B2 (en) | Compositions and methods for treatment of melanoma | |
US20140045924A1 (en) | Melanoma treatments | |
CN112011620A (zh) | circ-SLC38A1作为靶点在抑制膀胱癌细胞药物中的应用 | |
CN111172290B (zh) | 肝细胞癌诊断和治疗的miRNA | |
CN112641797B (zh) | 抑制结直肠癌生长、转移的靶标与诊断标志物及其应用 | |
CN113151280A (zh) | 一种小分子非编码rna及宿主基因在胃癌诊断及治疗的应用 | |
CN115666590A (zh) | 口腔鳞癌相关生物标志物及诊断和治疗方法 | |
CN105671195B (zh) | miR-520c核苷酸的用途、药物组合物和试剂盒 | |
CN111088357A (zh) | 针对escc的肿瘤标志物及其应用 | |
CN114606233B (zh) | 靶向长链非编码RNA HOXD-AS2的siRNA及其在肝癌治疗中的应用 | |
CN115261482B (zh) | miR-4256在胃癌治疗、诊断以及预后评估中的应用 | |
CN112852965B (zh) | lnc-ZNF100-5功能性表达抑制剂在制备治疗乳腺癌的药物中的应用 | |
CN113122638B (zh) | 一种hsa-novel_circ_0006787分子在肝癌治疗中的应用 | |
CN115074438A (zh) | 环状RNA circTFDP2及其siRNA在诊断、治疗前列腺癌中的应用 | |
CN115725736A (zh) | 一种诊断和治疗肝癌的circRNA标志物及其应用 | |
Chiacchiarini | miR-139-5p-PI3K/AKT/mTORC1 network has a role in supratentorial pediatric Low Grade Gliomas (pLGGs) | |
CN105582548B (zh) | 人uba2基因的用途及其相关药物 | |
CN115838801A (zh) | 一种用于胰腺癌诊断及治疗的circRNA及其应用 | |
CN117562917A (zh) | Stambpl1基因在制备治疗肺癌发生药物及诊断试剂盒中的应用 | |
CN115927611A (zh) | 一种乳腺癌的生物标志物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |